Influenza pandemic surveillance

Strong M, Burrows J, Stedman E, Redgrave P. Adverse drug effects following oseltamivir mass treatment and prophylaxis in a school outbreak of 2009 pandemic influenza A(HINI) in June 2009, Sheffield, United Kingdom. Euro Surveill 2010 15(19) pii/19565. 

Concerns have been raised about the use of adjuvanted pandemic vaccines in patients with immune disorders, such as immunodeficiency, autoimmune disorders, and solid organ transplants. To date, postmarketing surveillance has not found evidence for causality of any adverse reactions in such patients. Viral infections, such as influenza, can lead to severe complications in immunocompromised patients. 

Kilander A, Rykkvin R, Dudman SG, Hungnes O (2010) Observed association between the HAl mutation D222G in the 2009 pandemic influenza A(HINI) virus and severe clinical outcome, Norway 2009-2010. Euro Surveill 15(9) pii=19498... 

When the pandemic influenza HlNl vaccines were authorised for use during the 2009/2010 flu season, there was only limited data on safety and immunogenicity available. Over the past years, an extensive amount of safety and efficacy data from postmarketing surveillance studies has been published. 

Candela S, PergoHzzi S, Ragni P, Cavuto S, NobiUo L, Di Mario S, et aL An early (3-6 weeks) active surveillance study to assess the safety of pandemic influenza vaccine Focetria in a province of Emflia-Romagna region, Italy - Part One. Vaccine 2013 31(10) 1431-7. 

---